Rubius Therapeutics to Announce First Quarter 2020 Financial Results
Rubius Therapeutics (Nasdaq:RUBY) will announce its first quarter 2020 financial results on May 11, 2020, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rubius Therapeutics (Nasdaq:RUBY) will announce its first quarter 2020 financial results on May 11, 2020, before the market opens. The company specializes in genetically engineered red blood cells to develop Red Cell Therapeutics™ for treating various diseases, notably cancer and autoimmune conditions. Notably, Rubius will not hold a teleconference following the release of its financial results. The company utilizes its proprietary RED PLATFORM® to create off-the-shelf therapies aimed at specific therapeutic areas. For more details, visit www.rubiustx.com.
Details
News Market Reaction – RUBY
The recorded move for RUBY in the trading session of this news was +0.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced plans to report first quarter 2020 financial results on Monday, May 11, 2020, before market open.
The company will not be conducting a teleconference in conjunction with its financial results press release.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com
Media Contact:
Dan Budwick
1AB
+1 (973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.